Intelligent Bio Solutions has entered a major global manufacturing partnership with Syrma Johari MedTech Ltd, a move set to sharply reduce costs, improve margins, and speed up its planned US market entry. Announced today, the agreement...
Hindustan Laboratories has filed IPO papers with SEBI, preparing for its market debut and signaling a strategic move to expand operations in India’s fast?growing generic drug market. The submission is made at a time when there is still a high...
Strides has made a decisive leadership move to speed up Strides Digital Transformation, appointing Yajuvendra Singh M R as Vice President of Digital Transformation. The appointment, announced today, signals the company’s sharper focus on using...
Semaglutide patent expiry is set to open a Rs 50 billion generic drug opportunity, boosting pharma revenues across India, regulated markets and emerging economies.
The Union Health Ministry is in discussions with state governments on the possibility of granting additional time to certain pharmaceutical manufacturers to comply with revised Good Manufacturing Practices (GMP) norms under Schedule M of the Drug...
Health ministry bans oral nimesulide above 100 mg for human use after DTAB and ICMR review, citing safety risks, second-line therapy use, and safer drug alternatives.
Dr. Reddy’s Labs receives a USFDA CRL for AVT03 denosumab biosimilar, citing manufacturing inspection issues, delaying approval in the key US biologics market.
Johnson & Johnson completes its $3.05 billion acquisition of Halda Therapeutics, strengthening its oncology pipeline with RIPTAC technology and expanding targeted cancer therapies.
Cupid has received in-principle approval from its Board of Directors to establish a new FMCG manufacturing facility in the Kingdom of Saudi Arabia (KSA), marking the company’s first manufacturing venture outside India.
Amneal Pharmaceuticals Inc. got an approval from the FDA for two denosumab biosimilars, growing their biosimilar offerings in the US.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")